FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3038180981> ?p ?o ?g. }

• W3038180981 endingPage "104716" @default.
• W3038180981 startingPage "104716" @default.
• W3038180981 abstract "Pancreatic cancer is a leading cause of cancer-related deaths in the U.S. Ninety percent of patients with stage IV pancreatic cancer die within one year of diagnosis due to complications of metastasis. A metastatic potential of cancer cells has been shown to be closely associated with formation of perinucleolar compartment (PNC). Metarrestin, a first-in-class PNC inhibitor, was evaluated for its toxicity, toxicokinetics, and safety pharmacology in beagle dogs following every other day oral (capsule) administration for 28 days to support its introduction into clinical trials. The study consisted of four dose groups: vehicle; 0.25, 0.75 and 1.50 mg/kg/dose. Metarrestin reached its maximum concentration in blood at 3 h (overall median Tmax) across all doses with a mean t1/2 over 168 h of 55.5 h. Dose dependent increase in systemic exposure (Cmax and AUClast) with no sex difference was observed on days 1 and 27. Metarrestin accumulated from Day 1 to Day 27 at all dose levels and in both sexes by an overall factor of about 2.34. No mortality occurred during the dosing period; however, treatment-related clinical signs of toxicity consisting of hypoactivity, shaking/shivering, thinness, irritability, salivation, abnormal gait, tremors, ataxia and intermittent seizure-like activity were seen in both sexes at mid and high dose groups. Treatment-related effects on body weight and food consumption were seen at the mid and high dose levels. Safety pharmacology study showed no treatment-related effects on blood pressure, heart rate, corrected QT, PR, RR, or QRS intervals, or respiratory function parameters (respiratory rate, tidal volume, minute volume). There were no histopathological changes observed, with the exception of transient thymic atrophy which was considered to be non-adverse. Based primarily on clinical signs of toxicity, the No Observed Adverse Effect Level (NOAEL) in dogs was considered to be 0.25 mg/kg metarrestin after every other day dosing for 28 days with a mean of male and female Cmax = 82.5 ng/mL and AUClast = 2521 h*ng/mL, on Day 27." @default.
• W3038180981 created "2020-07-10" @default.
• W3038180981 creator A5025670544 @default.
• W3038180981 creator A5028439777 @default.
• W3038180981 creator A5049943739 @default.
• W3038180981 creator A5056910403 @default.
• W3038180981 creator A5061998470 @default.
• W3038180981 date "2020-10-01" @default.
• W3038180981 modified "2023-10-17" @default.
• W3038180981 title "Safety assessment of metarrestin in dogs: A clinical candidate targeting a subnuclear structure unique to metastatic cancer cells" @default.
• W3038180981 cites W1484110055 @default.
• W3038180981 cites W1491280455 @default.
• W3038180981 cites W1493871051 @default.
• W3038180981 cites W1912567622 @default.
• W3038180981 cites W1968812902 @default.
• W3038180981 cites W1974558715 @default.
• W3038180981 cites W1995849691 @default.
• W3038180981 cites W2003891406 @default.
• W3038180981 cites W2008634556 @default.
• W3038180981 cites W2020774741 @default.
• W3038180981 cites W2032923985 @default.
• W3038180981 cites W2055681053 @default.
• W3038180981 cites W2061842004 @default.
• W3038180981 cites W2072689499 @default.
• W3038180981 cites W2079052949 @default.
• W3038180981 cites W2107780185 @default.
• W3038180981 cites W2112171159 @default.
• W3038180981 cites W2113871357 @default.
• W3038180981 cites W2113927644 @default.
• W3038180981 cites W2135204824 @default.
• W3038180981 cites W2140080780 @default.
• W3038180981 cites W2150947558 @default.
• W3038180981 cites W2151291255 @default.
• W3038180981 cites W2153208546 @default.
• W3038180981 cites W2155563954 @default.
• W3038180981 cites W2165204241 @default.
• W3038180981 cites W2280294155 @default.
• W3038180981 cites W2605323150 @default.
• W3038180981 cites W2754177295 @default.
• W3038180981 cites W2803291242 @default.
• W3038180981 cites W2803723273 @default.
• W3038180981 cites W2896707256 @default.
• W3038180981 cites W2897057358 @default.
• W3038180981 cites W2899511895 @default.
• W3038180981 cites W2911188335 @default.
• W3038180981 cites W4211214747 @default.
• W3038180981 cites W98437133 @default.
• W3038180981 doi "https://doi.org/10.1016/j.yrtph.2020.104716" @default.
• W3038180981 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8378239" @default.
• W3038180981 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32619635" @default.
• W3038180981 hasPublicationYear "2020" @default.
• W3038180981 type Work @default.
• W3038180981 sameAs 3038180981 @default.
• W3038180981 citedByCount "3" @default.
• W3038180981 countsByYear W30381809812023 @default.
• W3038180981 crossrefType "journal-article" @default.
• W3038180981 hasAuthorship W3038180981A5025670544 @default.
• W3038180981 hasAuthorship W3038180981A5028439777 @default.
• W3038180981 hasAuthorship W3038180981A5049943739 @default.
• W3038180981 hasAuthorship W3038180981A5056910403 @default.
• W3038180981 hasAuthorship W3038180981A5061998470 @default.
• W3038180981 hasBestOaLocation W30381809812 @default.
• W3038180981 hasConcept C112705442 @default.
• W3038180981 hasConcept C121608353 @default.
• W3038180981 hasConcept C126322002 @default.
• W3038180981 hasConcept C22979827 @default.
• W3038180981 hasConcept C2776820430 @default.
• W3038180981 hasConcept C2777288759 @default.
• W3038180981 hasConcept C2779424989 @default.
• W3038180981 hasConcept C2780210213 @default.
• W3038180981 hasConcept C29730261 @default.
• W3038180981 hasConcept C42407357 @default.
• W3038180981 hasConcept C71924100 @default.
• W3038180981 hasConcept C90924648 @default.
• W3038180981 hasConceptScore W3038180981C112705442 @default.
• W3038180981 hasConceptScore W3038180981C121608353 @default.
• W3038180981 hasConceptScore W3038180981C126322002 @default.
• W3038180981 hasConceptScore W3038180981C22979827 @default.
• W3038180981 hasConceptScore W3038180981C2776820430 @default.
• W3038180981 hasConceptScore W3038180981C2777288759 @default.
• W3038180981 hasConceptScore W3038180981C2779424989 @default.
• W3038180981 hasConceptScore W3038180981C2780210213 @default.
• W3038180981 hasConceptScore W3038180981C29730261 @default.
• W3038180981 hasConceptScore W3038180981C42407357 @default.
• W3038180981 hasConceptScore W3038180981C71924100 @default.
• W3038180981 hasConceptScore W3038180981C90924648 @default.
• W3038180981 hasFunder F4320315952 @default.
• W3038180981 hasFunder F4320337351 @default.
• W3038180981 hasLocation W30381809811 @default.
• W3038180981 hasLocation W30381809812 @default.
• W3038180981 hasOpenAccess W3038180981 @default.
• W3038180981 hasPrimaryLocation W30381809811 @default.
• W3038180981 hasRelatedWork W1530166373 @default.
• W3038180981 hasRelatedWork W1993820209 @default.
• W3038180981 hasRelatedWork W2038856313 @default.
• W3038180981 hasRelatedWork W2046739556 @default.
• W3038180981 hasRelatedWork W2354875722 @default.
• W3038180981 hasRelatedWork W2378266540 @default.

• next